Member Info for TerrorWit

"The level of secrecy and non disclosure is a problem"

---------------------

Respectfully, that perspective misunderstands the role of a listed company in a sensitive, IP-driven sector.

The issue isn't a "level of secrecy"—it's mandatory confidentiality. Publicly disclosing JDA partner identities, ongoing litigation strategy, or detailed negotiation terms would violate NDAs, compromise competitive advantage, and could materially harm the company's ability to create value.

The board provides RNS updates on all material developments as required. Their duty is to steward the company, not to host a daily podcast for shareholder anxiety.

In this phase, with active litigation and commercial negotiations, what some call "secrecy" is, in fact, necessary operational discipline

When a stock trades below net cash, the market is making a explicit bet: it expects the company to destroy all shareholder value beyond the cash balance.

For NANO, that means the market is assigning:

- A negative value to the ongoing Shoei patent lawsuit.

- A negative value to two funded JDAs with major Asian partners.

- A negative value to the entire IP portfolio.

- A 100% probability that management will burn all cash without a settlement or JDA success.

This is a radical, binary bet on total failure. The investment case is a bet that this market assessment is wrong, and that the non-cash assets have positive value. The catalysts to prove it are known and funded."

Saldog and others

A key principle in IP strategy is that enforcement timing is a lever, not a reflex.

The goal isn't to sue at the first sign of infringement—it's to allow the situation to mature until the infringer has a substantial, vested business to protect. This achieves two things:

1. It maximizes potential recovery (damages are based on accrued profit).

2. It multiplies leverage (the threat of an injunction becomes existential, not just costly).

What can look like "delay" or "inaction" is often strategic patience. It allows market and regulatory pressures (like cadmium bans) to build, making settlement the only rational path forward for a mature infringer with committed customers.

In this light, the sequence—Samsung validation, LG settlement, then the focused Shoei suit—aligns with a deliberate escalation against a target whose stakes (and potential payout) have grown significantly

This is the critical point. Litigation is often a function of timing. The cadmiun ban deadlines turn Nanoco's IP from a legal asset into a compliance key for the entire supply chain. That's why this is happening now. Shoei's customers aren't just asking for legal clarification—they're demanding a compliant solution for their future production. This elevates the stakes from a royalty negotiation to a license-to-operate discussion. It's the ultimate leverage.

You're comparing two different companies.

Dec 2023: A pre-revenue R&D firm hoping for licensing deals, with unresolved litigation and an unproven commercial model.

Jan 2026: A litigation-financed IP holder with £14m+ net cash, a 3-year runway, two funded JDAs with major Asian partners, a national security-grade patent portfolio, and an active high-stakes trial set for this year.

The share price reflects the market's failure to price this transformation, not a failure of the transformation itself. The past price is irrelevant. The forward view is binary and funded: the Virginia trial.

The analysis isn't about where the price was. It's about what the company is, and what catalyst comes next.

Personally, I think there's a high probablitly that this week's pivot was Jalal's final negotiating tactic. He's a serious individual.

Subject: RE: RNS - The Two Ignored Strategic Facts

The market is reacting to the headline. The forum is reacting to emotion. Both are missing the two strategic facts buried in the RNS that change the narrative entirely.

1. The Board's Explicit Choice: The RNS does not say "we failed to sell." It says a sale is "unlikely to deliver a compelling transaction when the Group could instead deliver comparable or superior value by carefully investing its resources." This is a deliberate pivot, not a surrender. The board is choosing a self-funded litigation and development path over a discounted, complex sale.

2. The National Security Signal: The mention of complications from "national security investment legislation" is not an excuse. It is a credibility-enhancing data point. It means a government considers the IP strategically significant enough to scrutinize. This validates the asset's grade, explains the sale complexity, and justifies the pivot.

The conclusion is clear: the board believes the value of the IP—when enforced through the ongoing lawsuit and developed via the JDAs—is greater in their own hands than any price a buyer was willing to pay under the shadow of litigation and regulatory review.

The investment case has not ended. It has simplified: it is now a pure play on the company's ability to win in Virginia.

The RNS and the docket are not isolated data points. They are parts of a single, coherent board-level strategic calculus. Ignore the noise; focus on the capital and legal logic.

1. The Litigation Finance Tell: A Signal of Confidence & Timeline.

The most revealing detail is in plain sight: Nanoco is funding this case from existing cash reserves, not via litigation finance. This decision signals two things:

· Financial Strength: They have the war chest (the LG settlement) and are willing to deploy it.

· Expected Timeline: Litigation finance is for long, costly wars of attrition. Opting against it indicates the Board's expectation of a more capital-efficient, near-term resolution—i.e., a settlement, not a multi-year trial.

2. The Counterclaim is a Negotiation, Not a Trial Argument.

This counterclaim is not the opening statement for a jury. It is the final, formalized term sheet presented to Shoei's board. Its message is: "You are infringing validated patents. The only questions are the price and the timing. We are prepared to spend our cash to prove it in court and increase that price. You can spend yours to reduce it. Let's negotiate." The RNS's refusal to specify a quantum is because the damage figure is the opening bid in that negotiation.

3. This Validates, Not Complicates, the CDX.

The RNS is exclusively about litigation. Its silence on the CDX is profoundly positive. It proves the Board is running two parallel value-unlocking tracks:

· Track A (Legal): Enforce and monetize the IP through leverage against Shoei.

· Track B (Strategic): Sell the company/IP via the CDX process.

These tracks are synergistic. A potential buyer now sees a management team actively defending and proving the value of the core asset in real-time, against a strategically trapped competitor.

Conclusion: The Board's actions—funding the fight themselves, launching an offensive counterclaim, and compartmentalizing this from the CDX—are those of a confident, strategically patient player executing a proven playbook. They are not reacting; they are orchestrating the endgame.

The forum's speculation on "why not sue earlier?" or "what about historic liability?" is a retreat into complexity to avoid this simple, powerful reality. The trap for Shoei, set by the Samsung and LG settlements and sprung by the EU Cadmium Ban, is now being closed by this legal action. The clock is set by the court's 2026 schedule and the Board's treasury decisions.

The game has entered its final, commercial phase.

The docket is now clear. This is not a procedural update; it is a strategic declaration.

Nanoco has not simply responded to Shoei's defensive lawsuit. They have filed a Counterclaim for patent infringement against Shoei Chemical Inc. and Shoei Electronic Materials, Inc.

This changes everything. Shoei sought a judgment to clear a cloud. Nanoco has responded by bringing the storm directly to them. This transforms the Virginia case from a defensive skirmish into a direct, offensive assertion of the IP that just secured settlements from Samsung and LG.

Three critical implications:

1. It Validates the "Trapped Player" Thesis Utterly: Shoei's pre-emptive strike has backfired spectacularly. They are now formal defendants in an active infringement case, with the same patents that extracted $150m+ from others asserted against them. This is the definition of a trap closing.

2. It Demonstrates Serious Commitment: The filing of six pro hac vice motions for specialized counsel shows Nanoco is committing serious resources from the LG war chest to this fight. This is not a company retreating or conserving cash above all else; it is a company confidently deploying capital to defend and enforce its core asset.

3. It Accelerates the Endgame: The court's scheduling order sets a "rocket docket" timeline, with key milestones through May 2026. This legal front will now move quickly, creating a powerful, near-term point of leverage. A party facing an active, expedited infringement suit from a patent-holder with a 100% trial record has a profoundly strong incentive to settle.

For the CDX process: this does not derail it; it supercharges it. A potential buyer now sees a management team vigorously defending the crown jewels, a competitor being placed under direct legal siege, and a clear regulatory deadline (EU ban) looming over that competitor's head. The IP is not just a portfolio; it is a weapon actively in use, proving its value in real time.

The bears' narrative of passivity, cash-hoarding, and weak defense is now obsolete. The company's action speaks for itself: aggressive, confident, and strategically precise.

The game has entered its final, decisive phase.

Kooba’s posts highlight a fundamental strategic contradiction that many are overlooking.

He notes Shoei's new "world's largest" factory and its financial heft, framing them as a "significant company" and, by implication, a logical acquirer. This is precisely what makes their legal action so revealing, and so foolish.

Launching an aggressive, pre-emptive declaratory judgment lawsuit in Virginia is an astoundingly poor way to begin a courtship.

Consider the optics and leverage from Nanoco's boardroom in Runcorn:

1. It Poisons the Well: You do not sue the company you wish to buy before you buy it, unless your goal is to cripple its value first. This action frames Shoei not as a partner, but as an adversarial litigant. It destroys trust and sets a hostile tone for any negotiation.

2. It Highlights Their Weakness, Not Strength: The lawsuit is a defensive move born of fear—fear of the IP that just cost their customer (LG) $5m, and fear of the EU regulatory shift. A confident, cash-rich strategic buyer would engage through the CDX process, not the courthouse. Choosing litigation first reveals their primary need is to negate Nanoco's IP, not acquire it.

3. It Undermines Their Own Argument as a Buyer: If, as some speculate, Shoei's goal is ultimately to own the IP, this lawsuit is value-destructive. It forces Nanoco to spend its war chest (the LG settlement) on a legal defense, diminishing the very asset Shoei might want. It's an irrational, emotional, or desperate strategy for a genuine acquirer.

The conclusion is clear: Shoei's lawsuit is not the opening move of a buyer. It is the last gasp of a trapped competitor trying to break the IP leverage that constrains its new factory and its future in the European market.

This action doesn't make them a more logical buyer; it makes them a more logical licensee—a party forced to the table by legal and regulatory pressure, seeking a settlement, not a merger. The CDX process is for a strategic buyer. Shoei, by its own actions, is defining itself as a litigant in need of a permit

Addendum to my post yesterday

Feeks’s reduction of the investment case to a cash burn count is not analysis. It is the predictable final act of a documented cycle.

His history is in the forum’s record: a three-year, $1 billion ramp, shouting down rational settlement estimates, followed by catastrophic cognitive dissonance when the ~$150m reality landed.

Having been profoundly wrong on the upside, he is now ideologically committed to being wrong on the downside. His current stance is not bearishness; it is a permanent, bitter grudge against the facts that disproved him.

Consider his posts not as commentary, but as a live case study in the dangers of ego-driven investment. The market prices assets. It also, eventually, prices pathology.

Feeks, thank you. You have perfectly illustrated the critical failure in reasoning that this board must overcome.

You state: "where immediate prospects are so vague and indeterminate the only rational investment pricing is to calculate the value of a diminishing cash pile."

This is not rational investment. This is intellectual capitulation.

True investment analysis exists precisely to navigate "vague and indeterminate" prospects by identifying asymmetries, leverage, and catalysts. It is the difference between a weathervane and a navigator. You have chosen to be the weathervane, pointing only to the prevailing wind of sentiment, and declared it the only rational direction.

Your method—reducing a company with a $150m+ litigation-validated IP portfolio, a major regulatory tailwind, and a formal strategic sale process to a simple cash burn calculation—is not sophisticated pessimism. It is analytical poverty. It is why you have been wrong for five years, watching from the sidelines as the foundational commercial facts (the Samsung/LG settlements, the EU ban, the Shoei lawsuit) have been laid, while you count pennies.

The market is a voting machine in the short term, often pricing exactly this kind of fearful myopia. It is a weighing machine in the long term, and it weighs assets and cash flows. Nanoco's cash is a finite runway. Its IP is a perpetual license to a future market being created by law (EU ban) and demand (SWIR sensing). One is trivial to model; the other is what warrants actual analysis.

As for your request about an AI prompt: the most valuable prompt I could offer you is this: "Analyze Nanoco Group PLC not as a cash burn vehicle, but as an IP licensor in a market undergoing a structural, regulatory-driven phase change, with a trapped competitor and a formal seller-led M&A process underway." Try it. You might discover there is more to investing than division.

You champion the "rational" pricing of despair. I champion the rational analysis of verifiable, strategic facts. The SP is where your market is. It is not where the asset's value is. That disparity is the entire opportunity.

The shift in conversation from strategic analysis to cash burn arithmetic and pessimistic speculation about the CDX is understandable, but it's a regression to the very mindset that has consistently mispriced this company.

Let's re-anchor to the established framework:

1. Valuation is Asymmetric, Not Absolute. Noting the share price is near cash confirms the market's failure, not Nanoco's. It is pricing a litigation-proven IP portfolio, a funded 3-year JDA with a clear pathway, and a strategic sale process at zero. The opportunity lies in that disconnect, not in fearing it.

2. The CDX Process Has a Known Timeline. The CEO guided a conclusion in 2025. We are at the endpoint of that guidance. Silence at this precise moment is regulatorily neutral. A complex, seller-led M&A process for a strategic IP asset does not conclude with a running commentary. To interpret the final days of a guided timeline as proof of failure is to ignore how these processes work.

3. The Legal Front is Active and Procedural. The Virginia docket shows a professional defense taking shape with a court-managed timeline. This is not a distraction; it is the parallel track of defending the very asset being shopped in the CDX.

The bear case has collapsed into fearing the lack of news and calculating monthly burn. The bull case remains based on verifiable facts: the IP that secured $155m, the EU ban that cripples competitors, the competitor's defensive lawsuit, and the historical strategic interest from a player like Apple.

Patience is a strategic weapon. The market is pricing despair. Your analysis should price logic.

You’ve now retreated to the only hill left: “Litigation has risk.”

This is not an insight. It is a truism. It is equally true for Shoei. The critical investor doesn't debate truisms; they assess probabilities and leverage.

Your entire argument now rests on the banal premise that “a judge and jury might not see it our way.” Let’s examine that through the lens of commercial reality, not fear:

1. The “Unfriendly Venue” is a Sign of Weakness, Not Strength. That Shoei fled Texas—the venue where Nanoco’s patents were already validated against two giants—is not a point for your “uncertainty” thesis. It is the single clearest evidence we have of Shoei’s assessment of their own risk. They are so fearful of the Texas precedent they’ve launched a pre-emptive strike elsewhere. You frame this as Nanoco being “on the defensive.” The market reads it as Shoei being terrified of the offensive that hasn’t even been filed yet.

2. You Dismiss the Only Evidence That Matters. To say “the court will not care... about previous settlement amounts” is to ignore the foundation of commercial law. Those settlements are not just money; they are established interpretations of the patent’s scope and value. They set a market price for infringement. While not directly binding in Virginia, they are a powerful, real-world benchmark that will hang over every minute of this proceeding. Shoei’s lawyers aren’t arguing in a vacuum; they’re arguing against $155 million worth of contrary commercial verdicts.

3. You Mistake the Stakes. This is not a binary “win/lose” that determines Nanoco’s fate. This is a leveraged negotiation. Nanoco enters this with: a war chest from previous wins, a regulatory tide (EU ban) washing in its favor, and a competitor acting from a position of demonstrated fear (fleeing Texas). Shoei enters this with: a customer who just paid off its IP rival, a product line facing regulatory obsolescence, and the need to spend millions to fight a patent that has already been paid for twice.

You are correct on one point: nothing is “GUARANTEED.” But investment isn’t about guarantees. It’s about asymmetric risk.

The current market cap prices in near-total failure. The evidence—legal precedents, regulatory shifts, and the competitor’s own desperate actions—points to a significantly higher probability of a favorable outcome, whether in court or, more likely, in a settlement forced by that very leverage.

You’ve moved from arguing facts to arguing fear. That tells every rational observer all they need to know about the strength of the bear case

The Nanosys blog post is a gift. It’s the trapped player writing the press release for their own captivity, and it perfectly illustrates the commercial distress at the heart of the Shoei/Nanosys entity.

Read it not for its triumphant tone, but for the catastrophic concessions buried between the lines:

1. It is an Obituary for Their Core Business Model: The entire post is a eulogy for "Exemption 39(a)." This was the regulatory loophole that allowed high-cadmium QDs to exist in Europe. It is now dead. The "clear signpost" they celebrate is, in fact, a roadblock erected directly in their historical path. Their technology is now legislatively obsolete for the EU market unless radically altered.

2. It Confirms a Costly, Forced Pivot: The line "the industry has invested heavily in lower cadmium and heavy metal free materials" is an admission of defensive, compliance-driven R&D. This represents immense sunk cost and effort simply to meet a new, restrictive baseline (100ppm) that their competitor, Nanoco, was already born meeting (0ppm). This is competitive disadvantage, crystallized.

3. The "Cadmium-Free" Logo is a Liability, Not an Asset: Bragging about a logo for products containing up to 100ppm of a restricted heavy metal is not the win they think it is. It is a permanent marketing and legal vulnerability—a "greenwashing" accusation waiting to happen. True, unambiguous 0ppm cadmium-free technology owns the moral, regulatory, and marketing high ground. This is Nanoco's native territory.

4. It Validates the Market Shift Toward Nanoco's IP Domain: Most tellingly, they note that "heavy metal free materials...lead the market with over 70 percent share." Let that sink in. The market is already voting with its wallet, moving decisively toward the very technological space where Nanoco holds the foundational, litigation-proven patents.

The Nanosys blog post is a masterpiece of spin, attempting to frame a forced retreat as a voluntary march. It does not demonstrate strength; it documents the immense commercial and technological pressure Shoei/Nanosys is under. This pressure is precisely what makes their declaratory judgment lawsuit a act of desperation, not confidence, and it is precisely what makes Nanoco's IP portfolio so valuable to a strategic buyer in the CDX process.

The bears are clinging to the tone of the blog. The rational investor sees the substance: a competitor admitting the world has changed to their disadvantage, and to our core holding's structural advantage.

You are asking the wrong question, and in doing so, revealing the fundamental flaw in your analysis.

Your exhaustive search for which company's name appears in a Ross Young tweet about an Apple screen is a profound distraction from the commercial and legal reality. It is the equivalent of studying the branding on lifeboats while ignoring the fact the ship is taking on water.

Let us be explicitly clear on what constitutes evidence in a commercial dispute:

1. Evidence of Infringement & Leverage: The $150m settlement from Samsung and the $5m settlement from LG are not "nuisance fees." They are considered commercial verdicts. They are the market pricing the cost of infringing Nanoco's core IP portfolio. This is the primary, overwhelming evidence. It established the value of the patents Shoei is now challenging.

2. Evidence of Shoei's Distress (The "Trapped Player" Thesis):

· The EU Cadmium Ban: This is not speculation. It is legislation. It creates an existential threat to any display supplier reliant on cadmium-based QDs for the European market. Shoei, via its Nanosys acquisition, is heavily exposed to this.

· The LG Settlement: LG, a Shoei customer, paid Nanoco. This is a catastrophic commercial event for a supplier. It means Shoei's product got its customer sued. This poisons the relationship and creates immense pressure on Shoei to "solve" its IP problem.

· Shoei's Lawsuit: A declaratory judgment action is a defensive, pre-emptive move by a party who fears being sued. It is the act of a player seeking to remove a cloud over its business. It is not the act of a confident market leader. It is the act of a trapped player trying to break out.

You demand a piece of paper saying "Shoei is insolvent." That is naive. Commercial distress is evidenced by actions and context: a looming regulatory ban, a key customer settling with your IP rival, and you launching a desperate legal Hail Mary.

As for Apple: Your obsession with which QD film is in the M4 MacBook Pro misses the strategic history. Apple invested in Nanoco's fab plant via a convertible loan and only wrote it off in 2019. This indicates a sustained, strategic interest in Nanoco's CFQD technology for sensors and displays. The relevant question for the CDX Process is not "Did Shoei supply this screen?" but "Which company owns the foundational, litigation-proven, cadmium-free IP that any serious player in this space will need to navigate the next decade?"

The answer to that is Nanoco. That is why a strategic buyer—of which Apple is a prime, historical candidate—would engage in the CDX process.

Your search for a supplier name in a tweet is noise. The commercial facts—settlements, regulations, defensive lawsuits, and historical strategic investment—are the signal.

You came looking for hope but are searching in the wrong place. Hope is not found in a Ross Young tweet. It is found in the cold, hard logic of IP leverage, regulatory shift, and strategi

An interesting strategic angle is that Nanoco's known past relationship with Apple might be more relevant than ever. If Apple is now a major CFQD end-user (per Ross Young), their most logical move isn't to become Nanoco's legal adversary, but to become its strategic partner or owner to secure the IP and supply. This could be a primary driver behind the CDX process's value. It would also explain a more calibrated legal strategy that doesn't directly target the entire ecosystem at once.

Buzzfledderjohn

Your position requires us to believe that Nanoco's board, fresh from a $150m win against Samsung, decided to embark on a fraudulent, speculative lawsuit against another giant, LG, with patents they knew were weak. And that LG's lawyers, after months of discovery, were somehow duped into a $5m settlement.

That's not analysis; it's a conspiracy theory that insults the professionalism of both companies. The simpler, rational explanation is the one supported by the Samsung precedent and the commercial outcome: Nanoco's patents are strong, LG's advisors recognized the liability, and they settled. Shoei are in distress.

The technical speculation is an entertaining diversion, but it rests on a single, absurd premise: that a forum poster's analysis of patent language outweighs the combined judgement of LG's hired legal and technical advisors, who had full access to the evidence and recommended a $5m settlement.

LG's team made a real-world, financial assessment of risk. Shoei is now in court precisely because of that assessment. Arguing over trace cadmium and MCC definitions is like debating the paint colour on a ship that has already struck the iceberg.

The commercial reality—the settled lawsuit, the poisoned customer relationship, the frozen sales—is the only evidence that matters. Shoei's legal filing is the sound of a company trying to argue with an invoice that has already been paid.

And it's possible, even likely, that LG have asked Shoei to reimburse the costs

Shoei's own website (https://www.shoeichem.co.jp/global/profile/index.html) reveals a telling financial snapshot:

· Capital: ¥480 million (~£2.3 million)

· Sales (FY24): ¥71,010 million (~£350 million)

This enormous disparity indicates a highly leveraged, asset-light business. Such a model depends on uninterrupted cash flow and thin margins to service debt and generate returns.

The commercial trap they are now in—with the EU ban destroying their legacy market and the LG settlement freezing their CFQD sales—threatens that cash flow directly. For a company structured like this, it's not a legal dispute; it's a solvency crisis.

The commercial reality for Shoei is now dire, irrespective of the legal technicalities.

Their investment in Nanosys has been filleted by two external events:

1. The EU Cadmium Ban: This destroys the legacy, high-cadmium market that likely formed the core of the business they acquired. It forces a total, urgent pivot to CFQDs—the very market where they have no legal certainty.

2. The LG Settlement: This is catastrophic. Their marquee customer has publicly paid $5m to the patent holder because of Shoei's supply. This brands Shoei's entire supply chain as legally toxic. No sensible manufacturer will now place an order without a court-guaranteed "freedom to operate."

Shoei is trapped. They can't sell the old product (banned), and they can't sell the new product (feared).

Compounding the crisis:

· Time is the enemy: Nanoco can contest jurisdiction, file motions, and appeal, dragging a "rocket docket" case out for years. Shoei's business cannot survive a prolonged freeze.

· Financial distress: If Shoei borrowed to fund the Nanosys acquisition, they now hold a rapidly depreciating asset with crumbling revenue, while facing legal bills and debt service, this could create an existential solvency crisis. Who knows, it might even end with Nanoco, or its CDX partner owning them, the BoD have the relevant expertise in Jalal to manage this.

Their lawsuit isn't an aggressive move from strength; it's a desperate, funded plea for clarity from a company whose commercial viability has been potentoinally invalidated overnight. The question is no longer whether Nanoco's patents are valid. It is how much, and how quickly, Shoei will pay to survive a negotiation where Nanoco controls the clock and the leverage.